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Abstract
Rationale The selective type IV phosphodiesterase inhibi-
tor, rolipram, has been shown to improve long-term
memory and can reverse the cholinergic deficit caused by
scopolamine. However, the underlying mechanisms of
action of rolipram remain obscure.
Objectives The present study investigates the effect of
rolipram in a serotonergic-deficit model of acute tryptophan
depletion(ATD). In addition, thelevelsof plasma tryptophan
(TRP) were compared to object recognition performance.
Materials and methods The experiments were conducted
using male Wistar rats. The time-dependent effect of ATD
treatment (a gelatin-based protein mixture) on plasma TRP
levels (0, 1, 3, and 6 h after injection) and object
recognition task (ORT) performance (0.5, 1, 3, and 6 h
after ATD treatment) was examined. The effect of rolipram
(0, 0.01, 0.03, and 0.1 mg/kg, i.p.) was tested in the
condition in which ATD induced a clear memory deficit.
Results ATD significantly lowered the plasma TRP ratio
(TRP/Σlarge neutral amino acid) with a maximum of 48%,
approximately 1 h after administration. Furthermore, ATD
impairs ORT performance when administered 3 h before
testing. Rolipram (0.1 mg/kg) reversed the memory deficit
induced by ATD in a dose-dependent manner.
Conclusions On the basis of previous studies and the
ability to reverse a serotonergic deficit, we suggest that
rolipram may act through elevation of cyclic adenosine
monophosphate levels and subsequent increase in neuro-
transmitter release.
Keywords Phosphodiesterase.PDE4.Rolipram.
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Introduction
Inhibition of phosphodiesterase type 4 (PDE4) leads to an
increase in intracellular cyclic adenosine monophosphate
(cAMP) availability (Silvestre et al. 1999). cAMP is an
important second messenger molecule in the process of
intracellular signal transduction mechanisms (Bailey et al.
1996). Several studies have shown that rolipram, a selective
PDE4 inhibitor, improves cognitive performance in young
rats (Blokland et al. 2006; Imanishi et al. 1997; Rose et al.
2005; Zhang et al. 2000, 2004) and ameliorates scopol-
amine-induced memory deficits (Egawa et al. 1997;
Imanishi et al. 1997;R u t t e ne ta l .2006;Z h a n ga n d
O’Donnell 2000).
In a previous study, we have shown that rolipram
reversed a scopolamine-induced deficit in an object
recognition task (ORT) in male Wistar rats (Rutten et al.
2006). It was suggested that these effects may be related to
the effects of elevated cAMP levels on neurotransmitter
release. There is also evidence that there is a link
between PDE4 inhibition and serotonergic neurotransmis-
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The adenylate cyclase activator forskolin, as well as 8-
bromo-cAMP, can enhance the electrically evoked release
of
3H-5-hydroxytryptamine (Schoffelmeer et al. 1985).
Thus, elevating cAMP levels by a selective PDE4 inhibitor
could exert a general facilitatory effect on 5-HT release.
Based on these findings, we argued that rolipram may also
reverse memory deficits induced by a lowered 5-HT
neurotransmission.
Acute tryptophan depletion (ATD) is a well-established
model to assess the role of serotonin in cognitive and
affective functioning (Booij et al. 2003). The neurotrans-
mitter serotonin is synthesized from its amino acid
precursor tryptophan (TRP), which is obtained from our
food. Free TRP is transported into the brain across the
blood–brain barrier, but has to compete for entrance with
five other large neutral amino acids (LNAAs: valine,
leucine, isoleucine, phenylalanine, and tyrosine). The ratio
of TRP and these other LNAAs (TRP/ΣLNAA ratio) is
thought to be a more sensitive index of brain TRP
availability (Fernstrom 1981; Wurtman et al. 1980). As 5-
HT is synthesized from TRP, through the rate-limiting
enzyme TRP-hydroxylase, the availability of TRP in the
brain determines the amount of central 5-HT (Wurtman et
al. 1980). Due to its reversible and non-intrusive effects, the
method of ATD can be repeatedly used in animals and
humans.
In humans, acute tryptophan depletion has a negative
effect on memory consolidation (Park et al. 1994; Riedel et
al. 1999; Schmitt et al. 2000). Furthermore, memory
impairments in the ORT have been observed in rats after
ATD (Lieben et al. 2004b, 2005). Therefore, we hypothe-
sized that rolipram could reverse an ATD-induced memory
deficit in rats by elevating 5-HT release in the brain.
In addition to this aim of the study, we further examined
the relation between peripheral TRP and memory perfor-
mance. We investigated the effects of different pretreatment
times of the TRP-depleted mixture on object recognition
memory. These data should provide more experimental
support for a relation between plasma TRP and, conse-
quently, central 5-HT and memory performance.
Materials and methods
Animals
All experimental procedures were approved by the local
ethical committee of the Maastricht University for animal
experiments according to governmental guidelines. A total
of 42 4-month-old male Wistar rats (Charles River, The
Netherlands) were used (410–450 g). Rats were randomly
assigned to either the biochemistry (n=18) or the behavior
group (n=24). In the biochemistry groups, the animals were
randomly subdivided over three treatment groups, i.e.,
saline, TRP+, or TRP− (n=6/group). The animals were
housed individually in standard type 3 Makrolon cages on
sawdust bedding in an air-conditioned room (about 20°C).
They were kept under a reversed 12/12-h light/dark cycle
(lights on from 18:00 to 6:00 hours) and had free access to
water. Rats were housed in the same room as where they
were tested. A radio, which played softly, provided
background noise in all rooms. All testing were done
between 9:00 and 17:00 hours.
Drugs and chemicals
The gelatin hydrolysate (Solugel C) was obtained from PB
Gelatins (Tessenderlo, Belgium). Glucodry 210 was
obtained from the Amylumgroup (Koog aan de Zaan, The
Netherlands). L-Tryptophan and rolipram were obtained
from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Kaliumchloride (KCl), calciumchloride-dihydrate
(CaCl2·2H2O), and 5-sulfosalicylic acid dihydrate were
purchased from Merck (Darmstadt, Germany).
Treatment
During a period of 2 weeks preceding the experiment, the
rats were handled and habituated to oral injections with
normal tap water (10 ml/kg). On experimental days, the rats
were not fed 14 h before treatment until the testing period
was completed. This was done to minimize the availability
of TRP from food, which would counteract the effects of
the ATD treatment. The rats were orally treated with a
protein–carbohydrate mixture containing TRP (TRP+
group; in which 0.28% TRP of the total protein was added
to the mixture) or one lacking TRP (TRP− group; no TRP
added to the mixture), or with saline. The composition of
the nutritional mixture is shown in Table 1.
In every experiment, each dose contained Solugel C at
4.0 g/kg and Glucodry at 2.0 g/kg of the body weight and
was given in a dose of 10 ml/kg between 8:30 and
12:30 hours. Blood samples were taken at baseline
(20 min before treatment) and 60, 180, and 360 min after
the first treatment. For the behavioral studies in the object
recognition task, the mixture was administered at different
time points (see below).
Rolipram was freshly suspended in 5% ethanol, 1%
tylose (methyl-cellulose), and 94% distilled water on every
experimental day. The following doses of rolipram were
tested: 0, 0.01, 0.03, or 0.1 mg/kg always in combination
with the TRP− mixture (3 h before the first trial, T1).
Rolipram was always administered 30 min before T1 (i.p.
injection, dose 2 ml/kg).
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For the determination of plasma amino acid levels, blood
samples were taken at resting values and repeated at several
points in time. Blood sampling was done via a tail-incision
method (Fluttert et al. 2000). Promptly after collection of
blood in sodium heparin tubes (Microvette® CB 300,
Sarstedt, Germany), the samples were kept on ice. After
centrifugation of the blood samples (at 4°C for 15 min at
3,000×g in a Hettich EBA 12 centrifuge), plasma was
deproteinized with cups containing dry 5-sulfosalicylic acid
(6 mg/100 μl plasma), and the protein was spun down.
Samples were frozen in liquid nitrogen and stored at −80°C.
Before analysis, samples were thawed at 4°C, vortex-mixed
vigorously, and centrifuged at 50,000×g in a Hereaus Model
Biogufe Stratos for 10 min at 4°C. From the clear
supernatant, 20 μl was mixed with 1,960 μl water and
20 μl norvaline and stored in the cooled (7°C) sample
compartment until analysis.
In addition to total plasma TRP, the concentrations of
several other amino acids were determined with a fully
automated high-performance liquid chromatography system
after precolumn derivatization with ophthaldialdehyde
(OPA; Van Eijk et al. 1993). OPA amino acids derivates
were quantified with fluorescence detection. The concen-
trations of the total plasma amino acids were expressed as
micromole per liter.
Object recognition memory
The object recognition test was performed as described
elsewhere (Prickaerts et al. 2002).The apparatus consisted
of a circular arena, 83 cm in diameter. Half of the 40-cm
high wall was made of gray polyvinyl chloride, the other
half of transparent polyvinyl chloride. A light bulb was
switched on during testing only and provided a light
intensity (20 lx) which was equal in the different parts of
the apparatus. Two objects were placed in a symmetrical
position about 10 cm away from the gray wall. We used
four different sets of objects. The different objects were: (1)
a cone consisting of a gray polyvinyl chloride base
(maximal diameter 18 cm) with a collar on top made of
brass (total height 16 cm), (2) a standard 1-l transparent
glass bottle (diameter 10 cm, height 22 cm) filled with
sand, (3) a massive metal cube (10.0×5.0×7.5 cm) with
two holes (diameter 1.9 cm), and (4) a massive aluminum
cube with a tapering top (13.0×8.0×8.0 cm). The objects
could not be displaced by a rat.
In the first week, the animals were handled daily and were
adapted to the procedure in 2 days; that is, they were allowed
to explore the apparatus (without any objects) twice for
3 min each day. In the two following weeks, the rats were
adapted to the testing and i.p. administration procedure by a
saline injection(0.4 ml) 30 min before the first trial until they
showed a stable discrimination performance, i.e., good
object discrimination (a d2 value of about 0.30, see below)
at a 1-h interval on two successive sessions. Subsequently,
testing of the drugs began.
A testing session comprised two trials. The duration of
each trial was 3 min. During the first trial (T1) the
apparatus contained two identical objects (samples). A rat
was always placed in the apparatus facing the wall in the
center of the transparent front segment. After the first
exploration period, the rat was put back in its home cage.
Subsequently, after a delay interval, the rat was put back in
the apparatus for the second trial (T2), but now with two
dissimilar objects, a familiar one (the sample) and a new
one. The times spent exploring each object during T1 and
T2 were recorded manually with a personal computer.
Exploration was defined as follows: directing the nose to
the object at a distance of no more than 2 cm and/or
touching the object with the nose. Sitting on the object was
not considered exploratory behavior. To avoid the presence
of olfactory trails, the objects were always thoroughly
cleaned with alcohol (70%). Moreover, each object was
available in triplicate so neither of the two objects from the
Table 1 Composition of mixture and determination of the amino
acids in gelatin-based protein (mol)
Mixture Composition
Protein (Solugel) in 100 ml water 100 g
Aspartic acid 4.8
Glutamic acid 10.3
Hydroxyproline 11.4
Serine 3.4
Glycine 23.2
Histidine 0.8
Arginine 10.0
Threonine 2.0
Alanine 10.4
Proline 12.0
Tyrosine 0.4
Valine 2.2
Methionine 0.7
Isoleucine 1.0
Leucine 2.5
Hydroxylysine 0.9
Phenylalanine 1.1
Lysine 2.9
Carbohydrate (Glucodry 210) in 80 ml water 50
KCl 0.094
CaCl2·2H2O 2.32
l-Tryptophan (TRP−group) 0
l-Tryptophan (TRP+ group) 0.28
The composition of the mixture (g) used in this experiment is
described in italic. The amino acid spectrum (%) of the Solugel
protein was obtained from PB Gelatins, Tessenderlo, Belgium.
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trial. In addition, all combinations and locations of objects
were used in a balanced manner to reduce potential biases
due to preferences for particular locations or objects.
As we expected ATD to impair memory performance,
we needed a delay interval at which normal rats discrim-
inate between the novel and familiar object. Therefore, we
selected a delay interval of 1 h, as Wistar rats show good
discrimination between the two objects after this interval
(Rutten et al. 2006). Furthermore, we hypothesized that
rolipram may reverse deficits induced by ATD in a 1-
h delay ORT. In 1 week, three testing sessions were given,
with a 48-h washout period in between. Tests were always
conducted on Mondays, Wednesdays, and Fridays.
In the first behavioral experiment, we investigated the
effects of administration with TRP+ or TRP− mixture at
different time points (i.e., 30 min, 1, 3, or 6 h) before
testing in the ORT. Each rat always participated in each
condition, and the order of test conditions was decided at
random.
The second behavioral experiment examined the effect of
rolipram (30 min before T1) on object recognition perfor-
mance in combination with the TRP− mixture at the most
effective time point (i.e., 3 h before T1). Thus, five treatment
conditions were tested, i.e., saline, vehicle and TRP−,
rolipram 0.01 mg/kg and TRP−, rolipram 0.03 mg/kg and
TRP−, and rolipram0.1 mg/kgand TRP−. Each rat wastested
in each condition, and the order of treatment conditions was
decided at random. The same animals (n=24) were used for
both behavioral experiments; thus, control conditions
(TRP+) from experiment 1 and saline from experiment 2
can be compared to each other.
Statistical analysis
Biochemistry
The mean concentrations of plasma amino acids were
determined for each treatment and time condition separate-
ly. The extent of reduction (expressed in absolute values
and in percentage decline from resting values) was
calculated for total plasma TRP concentrations and for the
TRP/ΣLNAA ratio. Extreme values, as determined by an
extremity test (see Dixon 1959), were excluded from
statistical analysis. Differences in plasma amino acid
concentrations were analyzed with a general linear model,
with main factor ‘treatment’ and repeated measure factor
‘time’. Separate one-way analyses of variance (ANOVA)
were performed to analyze differences between treatment
conditions per time point. A post-hoc Bonferroni test was
used to further characterize the differences between
treatment conditions. Differences were regarded as statisti-
cally significant if P<0.05.
Behavior
The basic measures were the times spent by rats exploring
an object during T1 and T2. Table 2 shows the measures
involved in the object recognition task (Prickaerts et al.
1997). e1 and e2 are measures of the total exploration time
of both objects during T1 and T2, respectively. d2 was
considered as index measures of discrimination between the
new and the familiar objects. d2 is a relative measure of
discrimination which corrects the difference between
exploring the old and the novel object for exploration
activity (e2) and appears to be independent of the total
exploration times (see Şık et al. 2003). In the object
recognition task, results are not reliable if an animal
explores both objects in the second trial for less than 5 s
(Şık et al. 2003). Therefore, in every session, animals that
explored less than 5 s in the second trial (i.e., e2<5) were
excluded from analysis. For all parameters, the effects of
the different treatment, time, and interactions were analyzed
with univariate ANOVA for the first experiment and one-
way ANOVA for the second experiment. Significant effects
were analyzed in more detail using the Bonferroni
correction. To compare control conditions, i.e., the TRP+
(3 h before the first trial) condition of the first experiment
with the saline condition of the second experiment, a t test
was performed. Differences were regarded as statistically
significant if P<0.05.
Results
Plasma TRP values
The plasma TRP/ΣLNAA ratio is shown in Fig. 1. TRP/
ΣLNAA levels changed over the 6 h [F(3,60) = 4.92; P<
0.01]. There was a treatment effect for TRP/ΣLNAA ratio
[F(2,60) = 36.72, P<0.01]. Post hoc analysis showed that
the TRP− condition was significantly different than the
TRP+ and the saline condition (Bonferroni, P<0.05). In
addition, the time × treatment interaction was also
significant for the TRP/ΣLNAA ratio [F(6,60) = 7.80; P<
0.01]. Separate one-way ANOVA analyses for each
treatment time point showed differences between treatment
Table 2 Measures involved in the object recognition test
Exploration Discrimination
e1 ¼ a1 þ a2 d2 ¼ b   a=e2
e2 ¼ a þ b
e1 is the measure of the time spent in exploring both identical objects
(a1 and a2) in T1; e2 is the measure of the time spent in exploring
both the familiar (a) and new object (b) in T2; d2 is the measure of
discrimination between the new and familiar objects.
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and the 3-h time point [F(2,16) = 6.79; P<0.01]. However,
no differences between treatment conditions were observed
at the baseline time point (−20 min) [F(2,15) = 2.03; n.s.]
or the 6-h time point [F(2.17) = 3.33; n.s.] (see Fig. 1).
Furthermore, post hoc analysis showed that the TRP/
ΣLNAA ratio of the TRP-treated animals was lower than
the TRP+- or saline-treated animals at the 1-h time point
(Bonferroni; P<0.01) and the 3-h time point (Bonferroni;
P<0.05).
Behavioral experiment 1
The effects of ATD on ORT performance are shown in Fig. 2
and Table 3. There was a general treatment effect on ORT
performance [F(1,165) = 36.44; P<0.01]. In addition, a
time effect was observed on ORT performance [F(3,165) =
2.86; P<0.05]. The time × treatment interaction was also
significant for the memory performance in the ORT
[F(3,165) = 4.47; P<0.01]. Separate analysis per treatment
condition showed that there was a significant time effect for
the TRP− condition [F(3,87) = 5.41; P<0.01] in memory
performance, but not for the TRP+ condition [F(3,84) =
1.77; P=n.s.]. Post hoc analysis showed that object
recognition performance was significantly impaired when
the TRP− mixture was administered 3 h before the first
trial.
Behavioral experiment 2
The effects of ATD in combination with rolipram on object
recognition performance are depicted in Fig. 3 and Table 4.
A dose-dependent increase in discrimination performance
was observed after treatment with rolipram [F(4,104) =
6.85; P<0.01]. Post hoc analysis showed that a dose of
0.1 mg/kg rolipram reversed the effects of TRP− treatment
(P<0.05). Rolipram treatment decreased exploration times
in the first trial [F(4,106) = 16.24; P<0.01], but had no
effect on exploration times in the second trial [F(4,106) =
1.53; n.s.; see Table 4). Post hoc analysis showed that for
all of the rolipram doses the exploration in the first trial was
lower than the saline control condition.
A comparison between the d2 values of the control
groups of the first and second experiment (TRP+ 3 h vs
Fig. 1 The effects of treatment time on the ratio plasma TRP/ΣLNAA
(mean values and SEM). Percentages indicate the difference from
baseline levels in the TRP− conditions. Asterisks indicate significant
differences from baseline (*P<0.05; **P<0.01)
Fig. 2 The effects of treatment time of TRP+ or TRP− on the
performance in object recognition task. Asterisks indicate a significant
impairment in object recognition performance (*P<0.05)
Table 3 Exploration times in the object recognition task at baseline
and after ATD
T1—30 min T1—1h T 1 —3h T 1 —6h
TRP+
e1 26.62 (2.09) 32.30 (1.37) 27.82 (2.06) 29.00 (2.50)
e2 33.64 (2.40) 49.78 (3.11)* 28.61 (2.39) 28.37 (2.15)
TRP−
e1 26.97 (2.11) 30.39 (1.78) 29.29 (1.66) 24.98 (1.53)
e2 39.26 (4.17) 37.32 (2.40) 30.06 (1.77) 28.91 (2.69)
*P<0.05 (indicates significant differences to the baseline group)
Fig. 3 The effects of rolipram treatment on ATD-induced deficits in
the object recognition task. Asterisks indicate a significant difference
in object recognition performance compared with the TRP− and
vehicle condition (**P<0.01). The 0.1-mg/kg dose of rolipram
reverses the ATD effect
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two control groups [t(38) = 0.906; n.s.].
Discussion
The present study shows that acute tryptophan depletion
results in reliable lowering of plasma TRP and the TRP/
ΣLNAA ratio. When rats were administered one dose
(10 ml/kg) of the TRP− mixture, depletion was maximal
(48%) 1 h after the treatment. The present data provide
strong evidence that blood TRP levels predict object
recognition performance and that ATD has only temporary
effects on TRP levels and memory performance. When
injected 3 h before T1, object recognition was maximally
impaired. This is in support of the results from the blood
TRP values (see above). Thus, TRP levels in the blood
seem to be related with behavioral performance in rats. As
previous studies have shown (Lieben et al. 2004a) a clear
relation between plasma TRP and central 5-HT, these data
provide further support that ATD can be used as a
serotonergic-deficit model in the object recognition task.
In the study by Lieben at al. (2004a,b), two doses of the
TRP− mixture (10 ml/kg) were administered, which
resulted in a 70% drop of the TRP/ΣLNAA ratio and in
memory impairment in the ORT. In contrast, the present
study showed that one dose of the TRP− mixture resulted in
a 48% drop in the TRP/ΣLNAA ratio, which was found to
induce memory impairment in the ORT. These findings
suggest that a 50% reduction in plasma TRP levels is
sufficient to impair object memory in rats.
In the first behavioral experiment, no effects on
exploration times in the ORT were observed, except from
an increase in exploration time in the second trial of the
TRP+ 1 h before T1 group. However, in the second
experiment, a dose-dependent decrease in the exploration
time of T1 was observed after treatment with rolipram.
Previous work from our group has shown that as long as
exploration in trial 1 is higher than 10 s, a reliable
discrimination index (d2) can be calculated (Şık et al.
2003). Furthermore, as can be seen when exploration times
are compared to d2 values, effects in exploration time are
independent of effects in d2 values (Şık et al. 2003).
Rolipram is known to have some sedative side effects (at
higher dosages >0.1 mg/kg) (Griebel et al. 1991; Silvestre
et al. 1999); nevertheless, the low dosages used in the
present study improved memory performance.
Rolipram has shown its pro-cognitive effects in several
behavioral models. We have shown that rolipram treatment
increases object memory in a time-dependent forgetting
paradigm (Rutten et al. 2006). In addition, rolipram
attenuated cholinergic deficits caused by scopolamine in
several behavioral tasks (Imanishi et al. 1997; Rutten et al.
2006; Silvestre et al. 1999; Zhang and O’Donnell 2000).
When rolipram (0.1 mg/kg) was administered in combina-
tion with the TRP− mixture (i.e., TRP− 3 h before T1 and
rolipram 30 min before T1), we found that it reversed the
effects of ATD. These are the first data suggesting that
rolipram can reverse a serotonergic-induced memory deficit
in rats.
Our previous study indicated that rolipram can reverse the
cholinergic deficit caused by scopolamine in the ORT
(Rutten et al. 2006). Remarkably, a similar dose of
0.1 mg/kg rolipram was capable of reversing the serotoner-
gic and cholinergic deficits in the object recognition task,
which might be explained by a non-specific working
mechanism of rolipram. Although the underlying mecha-
nisms of action of the memory-enhancing effects of
rolipram in these models remain to be determined, the
present data could be explained via an enhanced cholinergic
and serotonergic turnover by rolipram (Imanishi et al. 1997;
Schoffelmeer et al. 1985).
Alternatively, the effects of rolipram could also be
explained in terms of only a cholinergic mechanism of
action. Thus, previous studies have shown that the
acetylcholinesterase inhibitor metrifonate ameliorates the
effects of ATD as well and improves performance in
scopolamine-deficit models of the ORT (Lieben et al.
2005). This suggests that the cholinergic and serotonergic
systems act in a synergistic manner in memory performance
(see Lieben et al. 2005 for a detailed discussion). Clearly,
further research is needed to scrutinize the mechanism of
action rolipram in the different animal models of memory.
Another mechanism of action of rolipram that could
explain the present data is related to the intracellular
signaling in long-term potentiation (LTP). In the hippocam-
pus, rolipram has shown to improve LTP through activation
of the cAMP/PKA/CREB pathway (Frey et al. 1993; Impey
Table 4 Exploration times in the object recognition task after treatment with rolipram and TRP− mixture
Saline Vehicle 0.01 mg/kg 0.03 mg/kg 0.1 mg/kg
Saline TRP− TRP− TRP− TRP−
e1 28.72 (2.52) 26.18 (1.72) 19.15 (1.66)* 18.68 (1.35)* 12.02 (1.53)*
e2 28.73 (1.42) 27.43 (1.80) 21.68 (1.96) 27.89 (2.63) 27.29 (2.70)
*P<0.05 (indicates significant differences to the baseline group)
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to behavioral improvement in several behavioral tasks
(Barad et al. 1998; Bernabeu et al. 1997; Blokland et al.
2006; Rutten et al. 2006). Consequently, it could be argued
that the present data could be explained by the effects of
rolipram on the cAMP/PKA/CREB pathway. However, a
recent study by our group showed that the administration
time of rolipram was of critical relevance. Rolipram was
only effective in the 24-h interval ORT when administered
3 h after T1 (Rutten et al. 2006), and the mechanism of late
LTP was proposed to explain these effects. However, in the
present study, a 1-h interval in the ORT was examined, in
which no gene transcription or protein synthesis is required.
Therefore, we assume that the cAMP/PKA/CREB pathway
cannot explain these effects.
A recent PET study used radioactive rolipram as a
measure for PDE4 binding and as an indirect index of
cAMP signaling (Lourenco et al. 2006). Acute elevation of
synaptic neurotransmitter levels (noradrenaline, 5-HT, and
histamine) resulted in elevated cAMP levels that in turn
elevated (R)-[
11C] rolipram binding to PDE4 (Lourenco et
al. 2006). According to this rationale, elevation of cAMP
levels through inhibition of PDE4 can reverse cAMP-
mediated deficits in behavior that occur due to a shortage of
5-HT, ie, reversing the ATD-induced object recognition
impairment. As rolipram non-selectively facilitates several
neurotransmitter systems, a broad mechanism of action can
be expected. This can be favorable because influencing
multiple systems increases the likelihood that several
aspects of behavior could be enhanced. This may explain
previous reports that rolipram was effective in depression
models (Bobon et al. 1988; Norman et al. 1992; Weishaar et
al. 1985). On the downside, the broad mechanism of action
increases the risks for negative side effects, e.g., emesis,
sedation, and nausea.
In summary, the method of ATD can be used as a
reliable method for inducing object memory impairment in
rats. The selective PDE4 inhibitor rolipram was able to
reverse this serotonergic deficit, which could be explained
by different mechanisms of action. These data provide
further support that PDE4 inhibition could be considered as
a potential target to improve memory performance.
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